Capula Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$531K Buy
+700
New +$529K ﹤0.01% 625
2026
Q2
– Sell
-500
Closed -$386K – 1057
2026
Q1
$386K Hold
500
– – ﹤0.01% 586
2025
Q4
$386K Buy
500
+100
+25% +$67.9K ﹤0.01% 434
2025
Q3
$225K Buy
400
+100
+33% +$56.5K ﹤0.01% 581
2025
Q2
$158K Hold
300
– – ﹤0.01% 421
2025
Q1
$190K Buy
+300
New +$206K ﹤0.01% 529
2024
Q4
– Sell
-200
Closed -$210K – 568
2024
Q3
$210K Buy
+200
New +$223K ﹤0.01% 369
2024
Q2
– Sell
-200
Closed -$192K – 622
2024
Q1
$192K Buy
+200
New +$190K ﹤0.01% 414
2023
Q4
– Sell
-2,000
Closed -$1.65M – 541
2023
Q3
$1.65M Buy
+2,000
New +$1.57M 0.03% 161
2022
Q2
– Sell
-17,500
Closed -$12.2M – 363
2022
Q1
$12.2M Buy
+17,500
New +$11.1M 0.17% 117
2021
Q2
– Sell
-13,400
Closed -$6.34M – 858
2021
Q1
$6.34M Buy
+13,400
New +$6.52M 0.13% 180

Other funds holding REGN

Capula Management's REGN Position: Q3 2026 in Review

Capula Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 276 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #867 among its holdings. This is a return to the name: Capula Management previously reported a position in REGN as recently as Q3 2025.

Capula Management first reported a position in REGN in Q1 2021 and has held it in 9 quarters since. The position peaked at $4.39M in Q1 2021. 1,432 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Capula Management held 276 shares of Regeneron Pharmaceuticals worth $209K as of Q3 2026.
  • Regeneron Pharmaceuticals was a new Capula Management position in Q3 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Capula Management's portfolio in Q3 2026, its #867 holding.
  • Capula Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 9 quarters since.
  • Capula Management's Regeneron Pharmaceuticals position peaked at $4.39M in Q1 2021.
  • 1,432 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Capula Management's 13F filing for Q3 2026, filed 16 Nov 2026.